DR LOVE: How does pazopanib fit into your current nonprotocol practice?

DR POLLACK: I use it. And as I said before, most of these patients go through multiple different treatments. So I find that for most of my patients that don’t have liposarcoma, they will get pazopanib at some point. But it has a progression-free survival benefit, but it’s not big a progression-free survival benefit. It’s a 3-month progression-free survival benefit.

So first of all, if you have a regular patient with nonadipocytic sarcoma, I’ll start with a doxorubicin-based therapy. And then usually off study, for a patient that’s — let’s say this is an undifferentiated pleomorphic sarcoma patient. So eribulin isn’t available to them. Trabectedin isn’t available to them. I’ll usually go to a gemcitabine-based treatment next. And then usually after that, that’s where I start to think about pazopanib.

Classification, incidence and management of sarcomas

Integration of the recently FDA-approved agents trabectedin and eribulin into the treatment algorithms for metastatic liposarcoma and leiomyosarcoma

Recent FDA approval of olaratumab in combination with doxorubicin and integration into the treatment algorithm for advanced STS

Role of tyrosine kinase inhibitors and immune checkpoint inhibitors in STS